Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5126-5137

  Lønning, Per E ^a   Geisler, Jürgen ^a   Krag, Lars E ^a   Erikstein, Bjørn ^a   Bremnes, Yngve ^a   Hagen, Anne I ^a   Schlichting, Ellen ^a   Lien, Ernst A ^a   Øfjord, Erik S ^a   Paolini, Jolanda ^a   Polli, Anna ^a   Massimini, Giorgio ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; CARBOXY TERMINAL TELOPEPTIDE; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; OSTEOCALCIN; PLACEBO; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE METABOLISM; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEMUR NECK; HEART DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; LIMB PAIN; LIPID BLOOD LEVEL; LIPID METABOLISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SWEATING; URINARY TRACT INFECTION; VAGINAL DRYNESS; VULVOVAGINAL DRYNESS; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY;

AGED; ANDROSTADIENES; AROMATASE INHIBITORS; BONE DENSITY; BONE RESORPTION; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE;

EID: 24644434439     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.097     Document Type: Article

References (48)

1. Clarke M, Collins R, Davies C, et al: Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348:1189-1196, 1996
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
3. Lønning PE, Kvinnsland S: Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35:685-710, 1988
4. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998
5. Geisler J, Haynes B, Anker G, et al: Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 20:751-757, 2002
6. Kaufmann M, Bajetta E, Dirix LY, et al: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18:1399-1411, 2000
7. Bonneterre J, Buzdar A, Nabholtz J-M, et al: Anastrozole is superior to Tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258, 2001
8. Mouridsen H, Gershanovick M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
9. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
10. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
11. Coombes RC, Hall E, Gibson LJ, et al: A randomized trials of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
12. Sirola J, Kroger H, Honkanen R, et al: Factors affecting bone loss around menopause in women without HRT: A prospective study. Maturitas 45:159-167, 2003
13. Carani C, Qin K, Simoni M, et al: Brief report: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95, 1997
14. Torgerson DJ, BellSyer SEM: Hormone replacement therapy and prevention of nonvertebral fractures; A meta-analysis of randomized trials. JAMA 285:2891-2897, 2001
15. World Health Organization. Assessment of fracture risk and application to screening for postmenopausal osteoporosis. Geneva, Switzerland, World Health Organization, 1994
16. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992
17. Harper-Wynne C, Ross G, Sacks N, et al: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614-621, 2002
18. Taxel P, Kennedy DG, Fall PM, et al: The effect of aromatase inhibition on sex steroids gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab 86:2869-2874, 2001
19. Prestwood KM, Kenny AM, Kleppinger A, et al: Ultralow-dose micronized 17 beta-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. JAMA 290:1042-1048, 2003
20. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996
21. Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991
22. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
23. Ahlborg HG, Johnell O, Turner CH, et al: Bone loss and bone size after menopause. N Engl J Med 349:327-334, 2003
24. Kanis JA, Johnell O, De Laet C, et al: International variation in hip fracture probabilities: Implications for risk assessment. J Bone Mineral Res 17:1237-1244, 2002
25. Kanis JA, McCloskey EV, Powles T, et al: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181, 1999
26. Pfeilschifter J, Diehl IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18:1570-1593, 2000
27. Goss PE, Qi S, Josse RG, et al: The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384-392, 2004
28. Heaney RP, Recker RR, Saville PD: Menopausal changes in bone remodeling. J Lab Clin Med 92:964-970, 1978
29. Looker AC, Bauer DC, Chesnut CH, et al: Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11:467-480, 2000
30. Bajetta E, Martinetti A, Zilembo N, et al: Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: Effects on estrogens and bone metabolism. Ann Oncol 13:1059-1066, 2002
31. Raisz LG, Wiita B, Artis A, et al: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81:37-43, 1996
32. Valimaki MJ, Laitinen KA, Tahtela RK, et al: The effects of transdermal estrogen therapy on bone mass and turnover in early postmenopausal smokers: A prospective, controlled study. Am J Obstet Gynecol 189:1213-1220, 2003
33. Johannessen DC, Engan T, di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997
34. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273:199-208, 1995
35. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
36. Alexander KP, Newby LK, Hellkamp AS, et al: Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 38:1-7, 2001
37. Viscoli CM, Brass LM, Kernan WN, et al: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243-1249, 2001
38. Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial. JAMA 291:1701-1712, 2004
39. Elisaf MS, Bairaktari ET, Nicolaides C, et al: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37:1510-1513, 2001
40. Gotto AM: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 144:533-542, 2002
41. Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 86:19L-22L, 2000
42. Hodis HN, Mack WJ, Azen SP, et al: Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349:535-545, 2003
43. Manson JE, Hsia J, Johnson KC, et al: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534, 2003
44. Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke. JAMA 288:2015-2023, 2002
45. Smolders RGV, van der Mooren MJ, Sipkema P, et al: Estrogens, homocysteine, vasodilatation and menopause: Basic mechanisms, interactions and clinical implications. Gynecol Endocrinol 17:339-354, 2003
46. Anker GB, Refsum H, Ueland PM, et al: Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clin Chem 45:252-256, 1999
47. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry - Scientific review. JAMA 288:1889-1897, 2002
48. U. S. Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 137:526-528, 2002